Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Tezcan Gecgil/Investing.com

  • Analysis & Opinion

Tezcan Gecgil/Investing.com 's Comment & Analysis
A complete archive of Tezcan Gecgil/Investing.com 's articles, including current analysis & opinion - Page 9

Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or derivatives. With a...
Berkshire Hathaway shares increased more than 18% since the beginning of 2022 In Q4, share buybacks totaled $6.9 billion Long-term investors could consider buying BRKb stock at current...
As the economic and geopolitical landscape shifts, investors have been reevaluating their portfolios. Metrics suggest that we have moved away from a bull market in many asset classes, especially...
The Bill & Melinda Gates Foundation is among the largest private philanthropic foundations worldwide. Established in 2000, it defines its primary objective as to: “Help all people lead...
Sunrun stock is down more than 17.5% since the beginning of 2022 Headwinds include supply chain issues and higher costs Long-term investors could consider buying the dips in RUN, especially towards...
After an incredible bull run at the beginning of the year, oil prices have recently declined. As we write, Brent oil is at $103, while US West Texas Intermediate, WTI, is trading below the...
Semiconductor giant NVIDIA has lost over 10% since January Supply chain constraints likely to persist, creating headwinds Long-term investors could consider buying the dip, especially if shares...
Increasing volatility on Wall Street and red-hot inflation levels have put exchange-traded funds (ETFs) that provide passive income in the spotlight. Today’s article introduces three high-yield...
Businesses led by their founders receive significant attention on Wall Street and in academia. For instance, according to research by Bain & Co. published in Harvard Business Review: “An...
Shares in Aptiv have slid almost 28% since January Recovery in production levels is expected in the second half 2022 Long-term investors could consider buying APTV at current levels Shareholders in...